Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eupraxia Pharmaceuticals Inc T.EPRX.WT


Primary Symbol: T.EPRX Alternate Symbol(s):  EPRX | T.EPRX.WT.A

Healthcare Biotechnology
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:EPRX)

Eupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

PR Newswire 5 days ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

PR Newswire 10 days ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

PR Newswire 11 days ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

PR Newswire 12 days ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

PR Newswire November 7, 2024

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

PR Newswire October 31, 2024

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

PR Newswire October 28, 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

PR Newswire October 15, 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

PR Newswire October 10, 2024
View More News ››

Opinion & Analysis (TSX:EPRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:EPRX)

Target price

  Raymond James target price is $18.00.
1northumberland - March 13, 2024

Raymond James - Lead Broker on Deal

Lets see if this US based brokerage can get the stock over issue
BeyondValuez - March 12, 2024

Someone doesn’t like something ?

Small amounts being dumped on alternate exchanges makes today look even worse. Not sure why?
Jmark1 - October 30, 2023

destruction

EPRX CFO was at Tekmira which held the delivery technology for the RNAi vaccines Tekmira is now Arbutus we are talking about the delivery...
kindvalue - August 17, 2021
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »